Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Mylan Suggests Downside To FDA's Efforts To Improve Generic Drug Review

Aug 09 2017

• By Derrick Gingery

US-Money-and-Pills_V2_1200x675

Related Content

ANDA Reviews: First-Cycle Desired, But Two-Cycles OK?

Jul 27 2015

EpiPen Familiarity May Prove Tough Hurdle For Generics

Sep 12 2016

FDA Pharmaceutical Quality Office Launches With Team-based Reviews

Jan 13 2015

Drug Pricing Panacea Or Just PR Victory? Expedited ANDAs May Have Limited Impact

Mar 21 2016

Generic Drugs: First-Cycle Review Times Improve, But Hundreds Of ANDAs Still Pending

Jul 04 2017

FDA's Off-Patent, Off-Exclusivity List Draws Few Takers Early On

Aug 05 2017

Complex Generics: Gottlieb Eyes FDA Policy Changes To Speed Approvals

Apr 06 2017

FDA's Generic Approvals Catch A Bit Of Breath In July But Continue At Fast Pace

Aug 07 2017

Implementing User Fees Should Be Lighter Lift For FDA This Time Around; Bill Heads To White House

Aug 03 2017

Generic Combination Products May Be Permitted Delivery Device Variations

Jun 05 2017

FDA Drug Pricing Policy Offers Short-Term PR Gain, More Long-Term Actual Benefit

Jun 28 2017

Related Companies

Viatris Inc.

Teva Pharmaceutical Industries Ltd.

GSK plc

Additional Topics

United States Generic Drugs Review Pathway Regulation FDA Pricing Debate BioPharmaceutical

More from Generics

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.